1Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea
4Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea
5Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA
6Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Copyright © 2025 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
Seung-Hwan Lee has been a managing editor of the Diabetes & Metabolism Journal since 2024. Yong-Moon Mark Park has been a statistical advisor of the Diabetes & Metabolism Journal since 2011. They were not involved in the review process of this article. Otherwise, there was no conflict of interest.
AUTHOR CONTRIBUTIONS
Conception or design: J.S.Y., K.H., S.H.L.
Acquisition, analysis, or interpretation of data: B.K., K.H., S.H.L.
Drafting the work or revising: K.S., H.S.K., J.H.C., Y.M.M.P., S.H.L.
Final approval of the manuscript: all authors.
FUNDING
This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Grant Number: 2022R1F1A1072279) and in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1 TR003107. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
ACKNOWLEDGMENTS
This work was performed by the cooperation with National Health Insurance Service (NHIS), and the National Health Information Database (NHID) made by NHIS was used. This study was performed as a Korean Diabetes Association–NHIS MOU project.
Values are presented as mean±standard deviation, number (%), or median (interquartile range). P values for the trend were <0.01 for all variables.
IDLA, individuals with diabetes living alone; CKD, chronic kidney disease; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate.
Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: adjusted for model 2+smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, and estimated glomerular filtration rate; Model 4: adjusted for model 3+duration of diabetes, insulin treatment, and oral antidiabetic medications.
IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; IDLA, individuals with diabetes living alone.
Adjusted for age, sex, smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, estimated glomerular filtration rate, duration of diabetes, insulin treatment, and oral antidiabetic medications.
IDLA, individuals with diabetes living alone; PY, person-year; HR, hazard ratio; CI, confidence interval; Q, quartile.
Adjusted for age, sex, smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, estimated glomerular filtration rate, duration of diabetes, insulin treatment, and oral antidiabetic medications.
IDLA, individuals with diabetes living alone; IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OAM, oral antidiabetic medication; DM, diabetes mellitus.
Characteristic | Total | IDLA (–) | IDLA (+) |
---|---|---|---|
Number | 2,432,613 | 2,177,477 | 255,136 |
Age, yr | 59.7±12.0 | 60.0±12.0 | 57.1±11.9 |
Male sex | 1,477,117 (60.7) | 1,320,781 (60.7) | 156,336 (61.3) |
Smoking | |||
Non | 1,332,065 (54.7) | 1,201,581 (55.2) | 130,484 (51.1) |
Ex | 551,677 (22.7) | 502,419 (23.1) | 49,258 (19.3) |
Current | 548,871 (22.6) | 473,477 (21.7) | 75,394 (29.6) |
Drinking | |||
Non | 1,399,724 (57.5) | 1,258,215 (57.8) | 141,509 (55.5) |
Mild | 810,413 (33.3) | 722,655 (33.2) | 87,758 (34.4) |
Heavy | 222,476 (9.2) | 196,607 (9.0) | 25,869 (10.1) |
Regular exercise | 529,781 (21.8) | 479,126 (22.0) | 50,655 (19.9) |
Low income | 514,787 (21.2) | 400,881 (18.4) | 113,906 (44.7) |
Hypertension | 1,412,106 (58.1) | 1,269,592 (58.3) | 142,514 (55.9) |
Dyslipidemia | 1,391,280 (57.2) | 1,249,187 (57.4) | 142,093 (55.7) |
CKD | 194,858 (8.0) | 177,372 (8.2) | 17,486 (6.9) |
Height, cm | 162.8±9.4 | 162.8±9.4 | 163.1±9.2 |
Weight, kg | 67.5±12.6 | 67.4±12.5 | 67.8±13.1 |
BMI, kg/m2 | 25.3±3.5 | 25.3±3.5 | 25.4±3.8 |
Waist circumference, cm | 86.2±9.0 | 86.2±8.9 | 86.1±9.5 |
Systolic BP, mm Hg | 128.5±15.0 | 128.5±15.0 | 128.1±15.3 |
Diastolic BP, mm Hg | 78.1±9.9 | 78.0±9.9 | 78.5±10.2 |
Fasting glucose, mg/dL | 144.5±45.6 | 144.1±45.0 | 147.9±49.8 |
Total cholesterol, mg/dL | 185.1±43.6 | 184.8±43.5 | 188.3±44.8 |
HDL-cholesterol, mg/dL | 50.9±14.7 | 50.9±14.6 | 51.2±15.4 |
LDL-cholesterol, mg/dL | 103.0±38.4 | 102.9±38.3 | 104.5±39.2 |
Triglyceride, mg/dL | 134 (93–197) | 134 (93–196) | 140 (96–208) |
eGFR, mL/min/1.73 m2 | 88.2±19.1 | 88.0±19.1 | 90.1±19.3 |
Insulin treatment | 237,716 (9.8) | 212,400 (9.8) | 25,316 (9.9) |
Oral antidiabetic medication ≥3 | 656,275 (27.0) | 589,113 (27.1) | 67,162 (26.3) |
Duration of diabetes, yr | 5.3±5.1 | 5.4±5.1 | 4.7±4.9 |
Variable | Number | No. of events | IR, /1,000 PY | HR (95% CI) |
|||
---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 4 | ||||
IDLA (–) | 2,177,477 | 23,707 | 1.90 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
IDLA (+) | 255,136 | 2,984 | 2.04 | 1.08 (1.04–1.11) | 1.21 (1.17–1.26) | 1.07 (1.03–1.11) | 1.10 (1.06–1.14) |
Income | IDLA | Number | No. of event | Incidence rate, /1,000 PY | HR (95% CI) |
|
---|---|---|---|---|---|---|
Risk trends | Effect modification | |||||
Medical aid | No | 28,360 | 588 | 3.70 | 1.50 (1.38–1.64) | 1 (Ref) |
Yes | 24,662 | 561 | 4.13 | 1.44 (1.32–1.57) | 0.96 (0.85–1.08) | |
Q1 | No | 372,521 | 4,215 | 1.96 | 1.10 (1.06–1.14) | 1 (Ref) |
Yes | 89,244 | 1,110 | 2.18 | 1.22 (1.15–1.30) | 1.11 (1.04–1.19) | |
Q2 | No | 398,511 | 4,295 | 1.87 | 1.12 (1.08–1.17) | 1 (Ref) |
Yes | 63,471 | 662 | 1.81 | 1.22 (1.13–1.32) | 1.09 (1.00–1.18) | |
Q3 | No | 559,452 | 5,874 | 1.83 | 1.05 (1.02–1.09) | 1 (Ref) |
Yes | 47,911 | 394 | 1.42 | 1.09 (0.98–1.21) | 1.04 (0.94–1.15) | |
Q4 | No | 818,633 | 8,735 | 1.86 | 1 (Ref) | 1 (Ref) |
Yes | 29,848 | 257 | 1.49 | 0.99 (0.88–1.12) | 0.99 (0.88–1.12) |
Subgroup | IDLA | Number | No. of event | IR, /1,000 PY | HR (95% CI) | P for interaction |
---|---|---|---|---|---|---|
Male | No | 1,320,781 | 15,763 | 2.09 | 1 (Ref) | 0.324 |
Yes | 156,336 | 2,073 | 2.33 | 1.12 (1.07–1.17) | ||
Female | No | 856,696 | 7,944 | 1.60 | 1 (Ref) | |
Yes | 98,800 | 911 | 1.59 | 1.07 (1.00–1.15) | ||
Age <65 yr | No | 1,397,390 | 10,761 | 1.32 | 1 (Ref) | 0.002 |
Yes | 190,240 | 1,932 | 1.76 | 1.16 (1.11–1.22) | ||
Age ≥65 yr | No | 780,087 | 12,946 | 2.99 | 1 (Ref) | |
Yes | 64,896 | 1,052 | 2.90 | 1.03 (0.96–1.09) | ||
Current smoking (–) | No | 1,704,000 | 18,946 | 1.93 | 1 (Ref) | 0.307 |
Yes | 179,742 | 2,052 | 1.98 | 1.09 (1.04–1.14) | ||
Current smoking (+) | No | 473,477 | 4,761 | 1.76 | 1 (Ref) | |
Yes | 75,394 | 932 | 2.18 | 1.14 (1.06–1.22) | ||
Alcohol consumption (–) | No | 1,258,215 | 16,916 | 2.36 | 1 (Ref) | <0.001 |
Yes | 141,509 | 2,011 | 2.49 | 1.05 (1.00–1.10) | ||
Alcohol consumption (+) | No | 919,262 | 6,791 | 1.27 | 1 (Ref) | |
Yes | 113,627 | 973 | 1.49 | 1.22 (1.14–1.31) | ||
Regular exercise (–) | No | 1,698,351 | 19,174 | 1.97 | 1 (Ref) | 0.839 |
Yes | 204,481 | 2,446 | 2.09 | 1.11 (1.06–1.15) | ||
Regular exercise (+) | No | 479,126 | 4,533 | 1.63 | 1 (Ref) | |
Yes | 50,655 | 538 | 1.84 | 1.09 (1–1.20) | ||
Obesity (–) | No | 1,064,991 | 12,510 | 2.06 | 1 (Ref) | 0.001 |
Yes | 123,931 | 1,642 | 2.33 | 1.17 (1.11–1.24) | ||
Obesity (+) | No | 1,112,486 | 11,197 | 1.74 | 1 (Ref) | |
Yes | 131,205 | 1,342 | 1.77 | 1.03 (0.97–1.09) | ||
CKD stage 1 (eGFR ≥90 mL/min/1.73 m2) | No | 1,105,432 | 2,903 | 0.45 | 1 (Ref) | <0.001 |
Yes | 139,349 | 474 | 0.59 | 1.30 (1.18–1.43) | ||
CKD stage 2 (60≤ eGFR <90 mL/min/1.73 m2) | No | 894,673 | 5,617 | 1.09 | 1 (Ref) | |
Yes | 98,301 | 795 | 1.41 | 1.22 (1.13–1.32) | ||
CKD stage 3 (30≤ eGFR <60 mL/min/1.73 m2) | No | 167,261 | 10,377 | 11.7 | 1 (Ref) | |
Yes | 16,449 | 1,189 | 13.6 | 1.06 (0.99–1.12) | ||
CKD stage 4–5 (eGFR <30 mL/min/1.73 m2) | No | 10,111 | 4,810 | 139.3 | 1 (Ref) | |
Yes | 1,037 | 526 | 149.8 | 0.94 (0.86–1.03) | ||
Insulin treatment (–) | No | 1,965,077 | 13,981 | 1.23 | 1 (Ref) | 0.134 |
Yes | 229,820 | 1,772 | 1.34 | 1.13 (1.07–1.19) | ||
Insulin treatment (+) | No | 212,400 | 9,726 | 8.56 | 1 (Ref) | |
Yes | 25,316 | 1,212 | 8.95 | 1.07 (1.00–1.13) | ||
OAM ≤2 | No | 1,588,364 | 14,543 | 1.59 | 1 (Ref) | 0.187 |
Yes | 187,974 | 1,795 | 1.66 | 1.08 (1.03–1.14) | ||
OAM ≥3 | No | 589,113 | 9,164 | 2.73 | 1 (Ref) | |
Yes | 67,162 | 1,189 | 3.11 | 1.14 (1.07–1.21) | ||
DM duration <5 yr | No | 1,162,352 | 3,927 | 0.58 | 1 (Ref) | 0.262 |
Yes | 149,400 | 602 | 0.70 | 1.13 (1.04–1.24) | ||
DM duration 5–10 yr | No | 455,896 | 4,225 | 1.61 | 1 (Ref) | |
Yes | 53,042 | 702 | 2.30 | 1.15 (1.06–1.25) | ||
DM duration ≥10 yr | No | 559,229 | 15,555 | 4.97 | 1 (Ref) | |
Yes | 52,694 | 1,680 | 5.71 | 1.07 (1.02–1.13) |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). IDLA, individuals with diabetes living alone; CKD, chronic kidney disease; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate.
Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: adjusted for model 2+smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, and estimated glomerular filtration rate; Model 4: adjusted for model 3+duration of diabetes, insulin treatment, and oral antidiabetic medications. IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; IDLA, individuals with diabetes living alone.
Adjusted for age, sex, smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, estimated glomerular filtration rate, duration of diabetes, insulin treatment, and oral antidiabetic medications. IDLA, individuals with diabetes living alone; PY, person-year; HR, hazard ratio; CI, confidence interval; Q, quartile.
Adjusted for age, sex, smoking, drinking, regular exercise, income, body mass index, hypertension, dyslipidemia, estimated glomerular filtration rate, duration of diabetes, insulin treatment, and oral antidiabetic medications. IDLA, individuals with diabetes living alone; IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OAM, oral antidiabetic medication; DM, diabetes mellitus.